Show simple item record

dc.contributor.authorDe la Cruz-Merino, Luis
dc.contributor.authorGrande-Pulido, E.
dc.contributor.authorAlbero-Tamarit, Ana
dc.contributor.authorCodes-Manuel de Villena, Manuel Eduardo
dc.description.abstractCancer may occur as a result of abnormal host immune system tolerance. Recent studies have confirmed the occurrence of spontaneous and induced antitumor immune responses expressed as the presence of tumor-infiltrating T cells in the tumor microenvironment in some cancer models. This finding has been recognized as a good prognostic factor in several types of tumors. Some chemotherapy agents, such as anthracyclines and gemcitabine, are effective boosters of the immune response through tumor-specific antigen overexpression after apoptotic tumor cell destruction. Other strategies, such as GM-CSF or interleukin-2, are pursued to increase immune cell availability in the tumor vicinity, and thus improve both antigen presentation and T-cell activation and proliferation. In addition, cytotoxic T lymphocyte antigen 4 – blocking monoclonal antibodies enhance immune activity by prolonging T-cell activation. Strategies to stimulate the dormant immune system against tumors are varied and warrant further investigation of their applications to cancer therapy in the
dc.publisherThe Oncologistspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.subjectTumor-infiltrating lymphocytesspa
dc.subjectImmune tolerancespa
dc.subjectCancer vaccinesspa
dc.titleCancer and Immune Response: Old and New Evidence for Future
dc.typejournal articlespa
dc.rights.accessRightsmetadata only accessspa
dc.description.extent751 KBspa

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España